Roivant Sciences (ROIV) Stock Price, News & Analysis

Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Key Stats

• Today's Range: $10.91 to $11.02
• 50-Day Range: $9.08 to $11.62
• 52-Week Range: $8.73 to $13.06
• Volume: 307,463 shs
• Average Volume: 5.57 million shs
• Market Capitalization: $7.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Buy

Roivant Sciences Stock Analysis - MarketRank™

Roivant Sciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 663rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Roivant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Roivant Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Roivant Sciences are expected to decrease in the coming year, from ($0.92) to ($1.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Roivant Sciences is -73.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Roivant Sciences is -73.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Roivant Sciences has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.03% of the float of Roivant Sciences has been sold short.

Short Interest Ratio / Days to Cover

Roivant Sciences has a short interest ratio ("days to cover") of 8.

Change versus previous month

Short interest in Roivant Sciences has recently increased by 2.95%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Roivant Sciences does not currently pay a dividend.

Dividend Growth

Roivant Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.03% of the float of Roivant Sciences has been sold short.

Short Interest Ratio / Days to Cover

Roivant Sciences has a short interest ratio ("days to cover") of 8.

Change versus previous month

Short interest in Roivant Sciences has recently increased by 2.95%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.44

News Sentiment

Roivant Sciences has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Roivant Sciences this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,355,035.00 in company stock.

Percentage Held by Insiders

Only 7.90% of the stock of Roivant Sciences is held by insiders.

Percentage Held by Institutions

64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ROIV Stock Analysis - Frequently Asked Questions

How have ROIV shares performed this year?

Roivant Sciences' stock was trading at $11.83 at the beginning of the year. Since then, ROIV shares have decreased by 7.0% and is now trading at $11.0050.
View the best growth stocks for 2025 here.

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) announced its quarterly earnings data on Monday, February, 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative trailing twelve-month return on equity of 14.05%.
Read the conference call transcript.

Who are Roivant Sciences' major shareholders?

Top institutional shareholders of Roivant Sciences include SB Investment Advisers UK Ltd. (8.67%), Vanguard Group Inc. (5.71%), Two Seas Capital LP (1.42%) and Invesco Ltd. (1.38%). Insiders that own company stock include Pharma Technologies Ltd Dexcel, Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Keith S Manchester, Eric Venker, Global Investors Lp Viking, Richard Pulik and Rakhi Kumar.
View institutional ownership trends.

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Roivant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/10/2025
• Today: 5/21/2025
• Next Earnings (Estimated): 5/29/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ROIV
• CIK: 1635088
• Web: roivant.com
• Phone: 44-20-7400-3347
• Fax: N/A
• Employees: 860
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.50
• High Stock Price Target: $22.00
• Low Stock Price Target: $12.50
• Potential Upside/Downside: +59.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.35 billion
• Net Margins: -119.54%
• Pretax Margin: -739.45%
• Return on Equity: -14.05%
• Return on Assets: -12.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 37.91
• Quick Ratio: 37.91

Sales & Book Value

• Annual Sales: $122.59 million
• Price / Sales: 64.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.76 per share
• Price / Book: 1.42

Miscellaneous

• Outstanding Shares: 713,549,000
• Free Float: 657,179,000
• Market Cap: $7.85 billion
• Optionable: Optionable
• Beta: 1.23